drugset / Trial / NCT02808429
Efficacy and Safety of Atacicept in IgA Nephropathy
Phase 2
Terminated
16 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.
Timeline
- Start
- 2017-01-31
- Primary completion
- 2020-02-07
- Completion
- 2020-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atacicept | Protein / enzyme biologic | 25 mg | Subcutaneous |
| Subject | Atacicept | Protein / enzyme biologic | 75 mg | Subcutaneous |